Brochure | January 4, 2024

ADCs: From Design To Development

Source: Abzena
GettyImages-1441786721-mAb-Antibody-monoclonal

Antibody-drug conjugates (ADCs) represent a burgeoning class of targeted therapeutics revolutionizing cancer treatment.  ADCs leverage the specificity of mAb and cytotoxicity of small molecule drugs to deliver efficacious payloads to precise areas. However, this class of drugs has been historically difficult to get through trials.

Explore how an experienced development and manufacturing partner with specialized teams can support running different stages in parallel to facilitate data sharing and clear communication, ultimately taking your ADC from design to development.

access the Brochure!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Abzena